Tendering process for pneumococcal conjugate vaccine: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| Line 23: | Line 23: | ||
[[Vertailuperusteet| Vertailuperusteet]], [[Epidemiological_modelling|Epidemiologinen mallinnus]] ja [[Taloudellinen_arviointi|Taloudellinen arviointi]]. | [[Vertailuperusteet| Vertailuperusteet]], [[Epidemiological_modelling|Epidemiologinen mallinnus]] ja [[Taloudellinen_arviointi|Taloudellinen arviointi]]. | ||
Comparison of vaccine products will be based on their price and expected effect(in Finnish: [[Vertailuperusteet|vertailuperusteet]]). | Comparison of vaccine products will be based on their price and expected effect(in Finnish: [[op_fi:Vertailuperusteet|vertailuperusteet]]). | ||
The epidemiological effect means the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the epidemiological effect is realised by using a [[Epidemiological_modelling|prediction model]]. The effectiveness of the vaccination programme will be quantified as the | The epidemiological effect means the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the epidemiological effect is realised by using a [[Epidemiological_modelling|prediction model]]. The effectiveness of the vaccination programme will be quantified as the | ||
expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most | expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most | ||
advantageous product will be chosen (in Finnish: [[Taloudellinen_arviointi|taloudellisen arvioinnin]]). | advantageous product will be chosen (in Finnish: [[Taloudellinen_arviointi|taloudellisen arvioinnin]]). | ||
Revision as of 17:26, 18 June 2014
| Moderator:Nobody (see all) Click here to sign up. |
|
|
| Upload data
|
Question
- How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine.
Scope
- We restrict the analysis to vaccination within the infant immunisation programme.
- We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: vertailuperusteet).
- The aim is to prepare selection criteria that lead to choice of the economically most advantageous tender.
- We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
- The preparation of the criteria is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines.
- The procurement can only involve a product that has trading license in Finland (see Lääkelain 20a§).
- The procurement must follow the Act on Public Procurement (julkisista hankinnoista annetun lain mukainen).
- The discussion on these pages does not bind the preparation of the procurement.
Answer
Rationale
The rationale has been summarised in the following 3 pages (currently in Finnish): Vertailuperusteet, Epidemiologinen mallinnus ja Taloudellinen arviointi.
Comparison of vaccine products will be based on their price and expected effect(in Finnish:). The epidemiological effect means the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the epidemiological effect is realised by using a prediction model. The effectiveness of the vaccination programme will be quantified as the expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most advantageous product will be chosen (in Finnish: taloudellisen arvioinnin).